Rapport Therapeutics, Inc. Common Stock (RAPP NASDAQ) stock market data APIs
$25.9747
-0.18(-0.7%)
as of November 13, 2026
Try our APIs with
free plan!
Rapport Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Prev. Close
25.9747
Open
25.7989
High
26.4656
Low
24.9571
52 wk Range
22.061-52.93
Market Cap
1 550 M
Shares Outstanding
59 280 K
Revenue
20 000 K
EPS
-0.84
Beta
1.402
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Rapport Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rapport Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Rapport Therapeutics, Inc. Common Stock Fundamental Data
Rapport Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue: 20 000 K
- EBITDA: -166 714 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Rapport Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-04
- EPS/Forecast: -1.21
Get Rapport Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rapport Therapeutics, Inc. Common Stock News
New
Buy the Dip: 5 Stocks Insiders Are Loading Up On After the Recent Market Sell-Off
Thursday, November 5 represented the worst trading session for the U.S. market in over a year. the Nasdaq Composite dropped 5.52%, the S&P 500 fell 4.36%, and the Dow shed 3.44%, as Wall Street's post...
Why Rapport Therapeutics (RAPP) Is Up 5.8% And What's Next
Rapport Therapeutics reported that RAP-219 achieved statistically significant primary and secondary endpoints in a Phase 2 trial for adults with acute mania in bipolar I disorder, with a 3.1 point pla...
Inside the $1 Billion Blockbuster Opportunity Sending Rapport Therapeutics Stock Higher
Positive trial data for Rapport’s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says. Continue Reading
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment. Continue Reading
Get Rapport Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.